Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.

•Lisdexamfetamine augmentation was not superior to placebo in reducing depressive symptoms.•The tolerability of lisdexamfetamine was consistent with published reports.•Study limitations include an inability to assess major depressive disorder symptom domains or subtypes.